The Polypill: From Promise to Pragmatism

* Starting with the promise and a brief history of the polypill, this article considers its current status and highlights five pragmatic issues to address before the polypill can become a mainstream strategy.

Uloženo v:

Podrobná bibliografie
Vydáno v:	PLoS medicine Ročník 12; číslo 8; s. e1001862
Hlavní autor:	Huffman, Mark D.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Public Library of Science 01.08.2015 Public Library of Science (PLoS)
Témata:	Analysis Blood pressure Cardiovascular Agents - administration & dosage Cardiovascular disease Cardiovascular Diseases - prevention & control Clinical medicine Clinical trials Clinical Trials as Topic Collaboration Disease prevention Drug dosages Enzymes Funding Heart attacks HIV Human immunodeficiency virus Humans Medication Adherence Pharmaceutical industry Pragmatism Primary Prevention Quality Secondary Prevention - methods Statins United States United States Food and Drug Administration Writers United States
ISSN:	1549-1676, 1549-1277, 1549-1676
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	* Starting with the promise and a brief history of the polypill, this article considers its current status and highlights five pragmatic issues to address before the polypill can become a mainstream strategy.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 I have read the journal's policy and have the following conflicts: I receive grant support from the World Heart Federation as senior program advisor for its Emerging Leaders program, which has received funding from AstraZeneca in the past and is current supported by Boehringer Ingelheim and Bupa, which are not manufacturers of fixed-dose combination therapy. I have led the 2012 and 2014 applications to the World Health Organization’s Model List of Essential Medicines for inclusion of fixed-dose combination therapy for the secondary prevention of cardiovascular diseases. I am also the senior author of the 2014 Cochrane systematic review on fixed-dose combination therapy and coordinating editor of the Cochrane Heart Group US Satellite at Northwestern. I also receive grant support from the National Heart, Lung, and Blood Institute for heart attack quality improvement clinical trial and from the National Cancer Institute for a smoking cessation clinical trial. I have also received travel support from the Cochrane Collaboration (Heart Group), American Heart Association, and World Heart Federation in the past two years. Wrote the first draft of the manuscript: MDH. Contributed to the writing of the manuscript: MDH. Agree with the manuscript’s results and conclusions: MDH. The author has read, and confirms that he meets, ICMJE criteria for authorship.
ISSN:	1549-1676 1549-1277 1549-1676
DOI:	10.1371/journal.pmed.1001862